Rallybio Corporation (RLYB)

Rallybio Corporation is a US-based clinical-stage biotechnology company focused on developing innovative therapies for patients suffering from severe and rare diseases. The company specializes in identifying, researching, developing, and advancing treatments targeting complement dysregulation and hematological disorders. Its lead product candidate, RLYB116, is an investigational complement C5 inhibitor designed to treat diseases associated with abnormal complement-system activity. Another product candidate, RLYB332, is a long-acting monoclonal antibody being developed to treat iron-overload disorders and severe anemias. The company conducts drug development, clinical research, and therapeutic innovation through collaborations with research institutions, academic medical centers, and biotechnology partners worldwide. Headquartered in New Haven, Connecticut, Rallybio operates primarily from the United States while collaborating internationally to develop potential treatments for patients with rare diseases. Its product candidates remain under development and are not established commercially marketed medicines.